A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : Nivolumab
- drug : Everolimus
Phase: Phase 3
Ages Eligible For Study:
- Men & women ?18 years of age - Histologic confirmation of renal cell carcinoma (RCC) with clear-cell component - Advanced/metastatic RCC - Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria - Received 1 or 2 prior anti-angiogenic therapy regimens in advanced or metastatic setting - No more than 3 total prior systemic treatment regimens in the advanced or metastatic setting, and evidence of progression on or after last treatment regimen received and within 6 months of enrollment - Karnofsky Performance Score ?70%